Nkarta Inc
NASDAQ:NKTX

Watchlist Manager
Nkarta Inc Logo
Nkarta Inc
NASDAQ:NKTX
Watchlist
Price: 2.41 USD -0.41% Market Closed
Market Cap: 170.1m USD
Have any thoughts about
Nkarta Inc?
Write Note

P/OCF
Price to OCF

-1.7
Current
-4.8
Median
22.1
Industry
Higher than median
Lower than industry value

Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.

P/OCF
-1.7
=
Market Cap
170.8m USD
/
Operating Cash Flow
-98.3m USD
All Countries
Close
Market Cap P/OCF
US
Nkarta Inc
NASDAQ:NKTX
170.8m USD -1.7
FR
Pharnext SCA
OTC:PNEXF
6T USD -239 142.2
US
Abbvie Inc
NYSE:ABBV
314.6B USD 19.1
US
Amgen Inc
NASDAQ:AMGN
141.2B USD 19.5
US
Gilead Sciences Inc
NASDAQ:GILD
117.2B USD 11.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.4B USD -125
US
Epizyme Inc
F:EPE
94.1B EUR -470.4
AU
CSL Ltd
ASX:CSL
136.4B AUD 30.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.4B USD 18.5
US
Seagen Inc
F:SGT
39.3B EUR -75.9
NL
argenx SE
XBRU:ARGX
36.2B EUR -145.2
 
US
Nkarta Inc
NASDAQ:NKTX
Average P/OCF: 19.9
Negative Multiple: -1.7
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -239 142.2
US
Abbvie Inc
NYSE:ABBV
19.1
US
Amgen Inc
NASDAQ:AMGN
19.5
US
Gilead Sciences Inc
NASDAQ:GILD
11.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -125
US
E
Epizyme Inc
F:EPE
Negative Multiple: -470.4
AU
CSL Ltd
ASX:CSL
30.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -75.9
NL
argenx SE
XBRU:ARGX
Negative Multiple: -145.2

P/OCF Forward Multiples

Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/OCF
N/A
2-Years Forward
P/OCF
N/A
3-Years Forward
P/OCF
N/A

See Also

Discover More